Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) Net Margin (2016 - 2024)

vTv Therapeutics' Net Margin history spans 10 years, with the latest figure at 21376.47% for Q4 2024.

  • For Q4 2024, Net Margin changed N/A year-over-year to 21376.47%; the TTM value through Sep 2025 reached 138058.82%, down 13622822.0%, while the annual FY2024 figure was 1815.34%, N/A changed from the prior year.
  • Net Margin for Q4 2024 was 21376.47% at vTv Therapeutics, down from 486.5% in the prior quarter.
  • Across five years, Net Margin topped out at 25.11% in Q4 2020 and bottomed at 89562.5% in Q1 2020.
  • The 4-year median for Net Margin is 15360.46% (2021), against an average of 26666.41%.
  • The largest YoY upside for Net Margin was 9833940bps in 2020 against a maximum downside of -8913014bps in 2020.
  • A 4-year view of Net Margin shows it stood at 25.11% in 2020, then plummeted by -312064bps to 78344.44% in 2021, then surged by 33bps to 52722.22% in 2022, then soared by 59bps to 21376.47% in 2024.
  • Per Business Quant, the three most recent readings for VTVT's Net Margin are 21376.47% (Q4 2024), 486.5% (Q1 2024), and 52722.22% (Q4 2022).